Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong ...

According to UNICEF's State of the World's Children 2023 report, in Latin America and the Caribbean, 6.8 million children did ...

The global Duchenne muscular dystrophy (DMD) therapeutics market is set to grow by $4.4 billion from 2024 to 2028, with a ...

US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the ...

BioCity Biopharma has reported positive Phase II results for SC0062 in treating IgA nephropathy, showing up to a 48.3% ...

US biotech major Gilead Sciences was trading nearly 2% higher in pre-market on Thursday after announcing its third-quarter ...

Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

Maryland-based MacroGenics, a biopharma focused on discovering, developing, manufacturing and commercializing innovative ...

US drugmaker Sarepta Therapeutic saw its shares gain 2.4% to $127.97 as it reported financial results for the third quarter ...

Oncology-focused biotech company Tango Therapeutics announced an update on its PRMT5 program. Tango noted that, based on ...

German pharma major Bayer’s independently operated subsidiary Asklepios BioPharmaceutical (AskBio) today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation ...

Moderna posted Q3 2024 revenues of $1.9 billion, up from $1.8 billion in Q3 2023, with net income reaching $13 million, a turnaround from last year’s $3.6 billion loss. Growth was driven by strong US ...